Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer
Original Article
M.R. Mirza, D.M. Chase, B.M. Slomovitz, R.d. Christensen, Z. Novák, D. Black, L. Gilbert, S. Sharma, G. Valabrega, L.M. Landrum, L.C. Hanker, A. Stuckey, I. Boere, M.A. Gold, A. Auranen, B. Pothuri, D. Cibula, C. McCourt, F. Raspagliesi, M.S. Shahin, S.E. Gill, B.J. Monk, J. Buscema, T.J. Herzog, L.J. Copeland, M. Tian, Z. He, S. Stevens, E. Zografos, R.L. Coleman, and M.A. Powell
N Engl J Med 2023;388:2145-2158
Available Credit
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation